Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr
News

Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024

  • By IPP Bureau | October 25, 2024

Piramal Pharma Limited has reported consolidated financial results for the period ended September 30, 2024.

Piramal Pharma has posted net profit of Rs. 22.59 crores for the period ended September 30, 2024 as against net loss of Rs. 88.64 crores for the period ended June 30, 2024.  The company posted net profit of Rs. 5.02 crores for the period ended September 30, 2023.

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024 as compared to Rs. 1,970.68 crores during the period ended June 30, 2024. The company reported total income of Rs. 1,960.57 crores during the period ended September 30, 2023.

For the Half Year ended FY25, Piramal Pharma has reported total income of Rs. 4,273.54 crores as compared to Rs. 3,747.73 crores during the 6 months period ended September 30, 2023.

Piramal Pharma has posted net loss of Rs. 66.05 crores for the 6 months period ended September 30, 2024 as against net loss of Rs. 93.56 crores for the 6 months period ended September 30, 2023.

Upcoming E-conference

Other Related stories

Startup

Digitization